Skip to main content

Table 1 Patient characteristics in all patients

From: Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease

 

Patients with COPD (n = 130)

LAMA/LABA

LAMA

p value*

No-BD

P value**

n = 64

n = 23

n = 43

Age

73.4 ± 6.7

70.6 ± 6.5

0.045

70.5 ± 6.2

0.027

Sex

     

 Male

50 (78.1)

19 (82.6)

0.644

39 (90.7)

0.088

 Female

14 (21.9)

4 (17.4)

 

4 (9.3)

 

Smoking status

     

 Current smoker

25 (39.0)

11 (47.8)

0.466

18 (41.9)

0.772

 Ex-smoker

39 (61.0)

12 (52.2)

 

25 (58.1)

 

Tobacco, pack-years

53.2 ± 27.3

60.6 ± 29.4

0.301

63.8 ± 40.2

0.052

Pulmonary function

     

 FEV1 (mL)

1787.5 ± 558.8

1429.5 ± 412.5

0.005

2168.8 ± 535.2

 < 0.001

 FEV1/FVC (%)

58.3 ± 9.6

53. 4 ± 11.4

0.049

61.4 ± 10.2

0.106

 FEV1%pred (%)

85.3 ± 22.6

64.3 ± 12.4

 < 0.001

94.6 ± 2.9

0.017

Severity of AFL

     

 Mild

32 (50.0)

1 (4.4)

 < 0.001

36 (83.7)

 < 0.001

 Moderate to severe

32 (50.0)

22 (95.6)

 

7 (16.3)

 

Comorbidities

     

 Cardiovascular disease

38 (59.4)

13 (56.5)

0.812

33 (76.7)

0.575

 Diabetes mellitus

17 (26.6)

6 (26.1)

0.964

12 (27.9)

0.878

Surgical procedure

     

 Pneumonectomy

1 (1.6)

0

0.367

0

0.844

 Lobectomy

56 (87.5)

23 (100.0)

 

40 (93.0)

 

 Segmentectomy

2 (3.1)

0

 

1 (2.3)

 

 Partial resection

5 (7.8)

0

 

2 (4.7)

 

Histology

     

 Adenocarcinoma

31 (48.4)

6 (26.1)

0.172

26 (60.5)

0.450

 Squamous cell carcinoma

28 (43.8)

14 (60.9)

 

15 (34.9)

 

 Other

5 (7.8)

3 (13.0)

 

2 (4.7)

 

Pathologic staging

     

 I

50 (78.1)

11 (47.8)

0.014

33 (76.7)

0.411

 II

8 (12.5)

9 (39.1)

 

3 (7.0)

 

 III

6 (9.4)

3 (13.0)

 

7 (16.3)

 

Recurrence (present)

7 (10.9)

11 (47.8)

 < 0.001

15 (34.9)

0.003

  1. Data are presented as n (%) or as mean ± SD
  2. COPD Chronic obstructive pulmonary disease; LAMA long-acting muscarinic antagonists; LABA long-acting β2-agonists; BD bronchodilator; FEV1 forced expiratory volume in 1 s; FEV1%pred percentage of predicted forced expiratory volume in 1 s; FVC forced vital capacity; AFL airflow limitation
  3. *Significance of LAMA/LABA versus LAMA
  4. **Significance of LAMA/LABA versus No-BD